Transparency, Please! MBTA Resists Disclosure of Arbitration Award

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Joe Selvaggi talks with attorney for Pioneer Public Interest Law Center (PPILC) John La Liberte, about the work he did to successfully gain access to the MBTA retirement fund’s arbitration agreement after a seven-month legal struggle.

Guest:

John La Liberte has been a litigator at a prestigious Boston boutique firm for over 30 years where he has also served as the firm’s general counsel. John
decided that he wanted to join Pioneer Public Interest Law Center to do what he hoped to do when he went to law school — engage in impact litigation.
WATCH:

Recent Episodes

Dobbs v. Jackson Supreme Court Case

This week on Hubwonk, host Joe Selvaggi talks with writer and historian Ramesh Ponnuru about the Supreme Court case, Dobbs v. Jackson Women’s Health Organization.

COVID’s Unintended Victims: Traditional Diseases Overlooked at the Public’s Peril

This week on Hubwonk, host Joe Selvaggi talks with Pioneer Institute’s Visiting Fellow in Life Sciences, Dr. Bill Smith, about his newest research paper, “An “Impending Tsunami” in Mortality from Traditional Diseases,” which sounds the alarm that the public health community’s focus on COVID-19 has caused many to avoid seeking medical attention for other illnesses. As a result, more Americans are dying from fear of COVID than from the disease itself.

Vaccine Development Renaissance: Pandemic Brings Niche Industry into Mainstream

This week on Hubwonk, host Joe Selvaggi talks with virologist, Dr. Peter Kolchinsky, about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease.

Shifting COVID-19 Goalposts: Moving from Zero Infections to Zero Deaths

This week on Hubwonk, host Joe Selvaggi talks with surgeon and author Dr. Marty Makary about the power and durability of vaccines, natural immunity and clinical therapies, that are overshadowed by the public health community's continued target of zero COVID-19 infections.